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Genomics, Rare Diseases, and Disruptive Innovation
in the Biopharmaceutical Industry
Mark J. Ahn, Amir Shaygan, Charles Weber
Portland State University, Portland, OR - USA
Abstract--The multinational biopharmaceutical industry has to
deal with significant financial pressures due to being a very costconstrained and highly regulated industry. To add to that, finite
patent expirations on financially successful drugs, vying nature of
the biotech industry due to new innovations. There has been an
increase of smaller markets due to the proliferation of molecular
segmentation patient populations in fields such as personalized
medicine. Particularly, due to the significant cost reducing impacts
of the development of “next-generation” sequence platforms on
DNA sequencing in the last decade, molecular diagnostics are
being considered as cost effective candidates to be used as a
standard medical test, in terms of risk assessment, confirmation of
diseases, and therapeutics. Biopharmaceutical companies need to
reassess their drug development strategies and choose among
alternative prospective business models in order to remain
relevant amid the new innovations and developments. Using a
dynamic capabilities lens, this paper tends to study the impact of
genomics generally and gene therapy specifically on the rare
disease sector of the biopharmaceutical industry by analyzing the
public data from 24 genomics based rare disease focused
biopharmaceutical companies. This study shows that growing
rates of cumulative returns is dependent upon the accumulation of
knowledge-based employees and expanding product portfolios of
disruptive genomics-based technologies for treating rare diseases.
Further, this study stresses the significance of structuring the
capability and capacity to absorb expertise and accrue knowledge
for new product innovations and viable competitive advantage.

I. INTRODUCTION
Multinational biopharmaceutical firms exist in an
increasingly cost-constrained and highly regulated ecosystem.
Concurrently, these companies have to cope with constant
competitions which is imposed upon them due to their
blockbuster drugs’ expirations followed by the imminent
emergence of generic drugs. They also exist in an environment
which possesses a very high innovation rate and companies can
lose their market monopoly due to new disruptive technologies.
Moreover, in the last decade, there has be an escalation in the
number of smaller markets due to the fall in the cost of DNA
sequencing in result of the development of “next-generation”
platforms and increase in genetic segmentation of patient
populations. Molecular diagnostics in particular are now being
considered as cost effective standard medical test options for
assessing risk and diseases confirmations—and increasingly, as
therapeutics for rare diseases as a result of DNA sequencing’s
affordability. Because of all these changes, it is imperative for
biopharmaceutical companies to reassess their drug
developments strategies and business models in order to stay
relevant and competitive in this unforgiving market.

In the recent years there has been a paradigm shift in big
multinational pharmaceutical companies’ models. Companies
like Merck, Pfizer, Roche, and Glaxo are no longer dismissing
the rare disease market due to its small addressable market and
targeted population. In contrast to the past, they are more
interested in investing in rare disease treatments. Even some
health systems are now focusing more on the importance of
genetic predispositions and genomics related data as part of
invigorating e delivery of care to the patients [1].
Currently, about 10% of Americans are dealing with
approximately 7,000 rare diseases (only 5% with approved
treatments) [2, 3]. Among a significant amount of technological
breakthroughs in the recent years, one that has undoubtedly
influenced the mentioned economic paradigm shift is the DNA
sequencing which is the mapping of the human genome. The
introduction of Sanger-based advances has caused the cost of
sequencing a human-sized genome to plummet substantially
from $100 million to $1,000 in the last three decades [4, 5]. This
new technology would mean substantially less amount of time
needed for patient testing, higher government financial
incentives, pediatric review voucher, and more approval rates
from US Food and Drug Administration [6].
The genomics revolution is expected to disrupt traditional
multinational pharmaceutical industry structure. In other words
the sole focus is not going to be relying on large, chronic drug
blockbusters targeted at large patient populations. Disruptive
innovations such as gene therapy can deliver single treatment
cures and can potentially shift the status quo in the
biopharmaceutical industry structure. Amid these changes,
biopharmaceutical companies are in great need to reprioritize
drug development strategies and carefully choose among future
business models options in order to stay competitive in a highvelocity market such as the biopharmaceutical industry. Using
a dynamic capabilities lens, this proceeding aims to study the
impacts of different financial, organizational, and productrelated resources on the enterprise value of genomics-based rare
disease-focused biopharmaceutical companies. In order to
pinpoint the influence of decreased cost and increased attraction
in genomics generally and gene therapies specifically (delivery
of single treatment cure using corrective genes for fatal rarediseases) on biopharmaceutical companies, the industry
background and the influence of genomics in rare diseases are
briefly studied. This study delves into capability and capacity
building rare disease-focused biopharma companies.
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45 were from US. Multinational biopharmaceutical companies
are stressing the significance of strategic alliances in bolstering
their pipelines (Ahn, et al., 2009; 2010).
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One of the more disruptive sub-sectors of the
biopharmaceutical industry is genomics which has an impact on
different parts of the industry. An example of this are the
companies that concentrate on single treatments for rare
diseases. Therefore, many companies are significantly
increasing R&D investment in genomics to penetrate the rare
diseases market and take advantage of the new opportunities in
treating unmet medical needs.
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Figure 1. Cost per genome evolution compared to hypothetical data reflecting
Moore’s Law [5]

II. THE BIOPHARMA INDUSTRY
The biopharmaceutical industry is a mixture of traditional
multinational drug manufacturers, biotechnology companies,
and distribution companies mainly focused on medicinal and
veterinary chemical and biological combinations. A
pharmaceutical firm can be defined as company that performs
commercial R&D, marketing, and distribution of drugs [7].
Biotechnology is defined as techniques for changing
microorganisms, and a biotechnology company focuses on
manipulating living cells (plants or animals) using biological
knowledge [8]. Pharmaceuticals and biotechnology
organizations are placed in a highly dynamic industries with
intense global competition, new product development (NPD)
plays a significant role in reaching success in these types of
companies [9]. Therefore, drug development companies have
been shifting their strategies from manipulating natural
compounds to use of new biologic understanding and tools in
order to come up with new drug ideas and bolster their pipelines
[10, 11].
New genomic insights and tools such as gene therapy,
regenerative medicine and molecular diagnostics are causing
significant industry paradigm shift from active disease
confirmation to treatment decision-making, avoidance and
wellness [12]. As one of the largest employers of scientists and
one of the highest levels of R&D among industries (increasing
R&D expenditure from $2.0 billion in 1980 to $51.4 billion in
2014 in US), the pharmaceuticals industry targets large global
markets [11, 13]. As an example, the United States possesses
86% of global biotech financing [14]. Some of the other traits
of the biopharmaceutical industry are lengthy drug
development wait times (10-12 years), low levels of successful
drug transformation from clinical trials to approved drugs (less
than 12%), high drug development costs (from $179 million in
1970s to $2.6 billion in 2000s-early 2010s), and high R&D
expenditure as fractions of sales (23.4% and 17.9% for domestic
and total sales respectively) [15, 16]. An Ernest & Young
(2016) noted that 78 biotech companies offered their initial
public offerings and raised $5.2 billion in their IPOs, of which

A. Genomics in Rare Disease Treatment?
Genomics is the scientific discipline of sequencing, mapping,
and characterization of human genes. This breakthrough has
had a significant impact on drug discovery and development in
the biopharmaceutical industry [17, 18]. Molecular genetics has
significantly advanced drug development from risk assessment,
early detection, and targeted therapies for needed medical
shortages [19].
In the last 20 years, the cost of sequencing a human-sized
genome has descended substantially from $100 million to about
$1,000. Sequencing industry leader Illumina is aiming for a
$100 genome while focusing on accurate next generation
sequencing (NGS) solutions, sequencing systems, and data
analysis. The accelerated change of speed and the fall of per
genome cost in the last decade reflects the shift from Sangerbased sequencing to next-generation genome sequencing
technologies [4]. The rise of NGS technologies has enabled the
generation of an enormous volume of data in a way more
reasonable way (up to 1 billion short reads per instrument run)
[20]. The information that genomics provides has the ability to
improve our understanding of disease biology, personalized
therapies and ,in result, better health decision making through
their combination with new technologies [21, 22].
The treatment of rare disease has been one of the biggest
and most disruptive opportunities for the progress in genomics.
Rare diseases provide researchers with smaller patient
populations, and can enable the cost effective development of
drugs for a non-homogeneous spectrum of diseases within a
specific genetic disorder [23]. Rare disease is defined by the
Rare Disease Act of 2002 as "any disease or condition that
affects fewer than 200,000 people in the US” [24]. Genomics is
facilitating researchers in better understanding the nature,
severity, rate of progression, and clinical presentation of these
diseases, many of which have impacts on pediatric populations.
In a more pragmatic way for smaller biopharma companies, the
increased interest in rare diseases is also provoked by smaller
clinical trial populations, increased government financial
incentives, and higher approval rates from US Food and Drug
Administration (FDA). FDA Commissioner Scott Gottlieb
noted that: “new guidance on the clinical evaluation of targeted
therapies for rare disease subsets by the FDA…will address the
issue of targeted drugs, and how we simplify the development
of drugs targeted to rare disorders that are driven by genetic

variations, and where diseases will all have a similar genetic
fingerprint” [25].
As an example, Avexis, Inc. is developing AVXS-101
(gene therapy) for the treatment of Spinal Muscular Atrophy
(SMA), which is uniformly fatal by 2 years of age [26]. This
disease is caused by a single genetic defect and Avexis has the
goal of alleviating or treating this disorder with the help of
single treatment gene therapy. Initial results presented in 2017
demonstrated that 15 of 15 (100%) patients were event-free at
13.6 months (versus an expected event-free survival rate based
on the natural history of the disease of 25%). Many companies
such as Avexis, Biomarin, Bluebird, Abeona, Dimension, and
Spark are targeting different debilitating, genetically-based rare
diseases.
Many biotech firms embark on strategic alliances with
larger firms to take advantage of the resources and attain
validation [27]. Bluebird bio’s partnership with Celgene; or
Spark Therapeutics partnership with Pfizer in the development
of SPK-9001 drug for the treatment of Hemophilia B are
examples of this organizational behavior [28]. Moreover, some
of these rare disease-focused biotech companies are co-located
in biotech clusters such as New England and California which
account for 17 of the 24 studied companies. Biotech clusters
enhance access to academic research centers, qualified
employees, experienced vendors and suppliers, informed life
science venture investors, and shared resource arrangements
[29, 30, 11, 31].
Ultimately, industry sectors rise by creating, building and
capturing value. While the biotech sector has dramatically
outperformed the S&P 500 index (which represents the US
stock market index based on the market capitalizations of 500
large companies having common stock listed on the NYSE or
NASDAQ), the Rare Disease sub-sector of the biotech market
has experienced extraordinary growth (Figure 2).
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Figure 2: Stock Market Performance: S&P 500
vs. Biotechnology v Rare Disease Companies

In conclusion, biopharmaceutical companies need to acquire
dynamic capabilities in order to recognize, assimilate,
transform, and exploit their tangible and intangible assets (tacit
knowledge, R&D know-how, NPD, alliances and acquisitions,
and skilled workforce attraction) in order to accelerate

innovation [32, 33]. Markets such as biopharmaceuticals are
finely tuned to recognize and assess value, assess and manage
risks and reward companies who innovate in targeted therapies
[34, 31]. The reason this study considers 24 companies is that
there are currently 24 rare-disease focused, and genomics-based
companies in the United States.
III. DYNAMIC CAPABILITIES
In the new technology-based era of NPD, faster information
flow, and easier and faster access to markets, managing and
orchestrating intangible assets are vital to building unique value
and competitive advantage [35]. Teece, Pisano & Shuen [36]
suggest that competitive advantage is built and protected not in
product markets but in markets for know-how and other
intangibles which they refer to as the dynamic capabilities.
There are multiple definitions of dynamic capabilities in the
literature. Pisano [37] defines them as organizational and
strategic routines that allow managers to change, jettison,
integrate, and re-connect resources in order to create new valuegenerating blueprints [38]. Dynamic capabilities are tools for
generating, evolving, and morphing of resources to attain
sustainable competitive advantage [36, 39]. By merging these
definitions, [40] defines dynamic capabilities as the company’s
organizational and strategic actions to use, integrate,
recombine, acquire and dispose of resources to equal or
generate market change as a response to emergence, evolution,
division, and demise of markets [41]. Some of these actions can
be alliances, acquisitions, NPD, and strategic decision-making
[42].
Moreover, Eisenhardt and Jeffrey [41] discuss multiple
common characteristics between dynamic capabilities across
high-tech organizations. Despite the fact that dynamic
capabilities differ across various firms, some traits such as
being “equi-final” (reaching dynamic capabilities from
different roads and being path dependent); “compatible”
(effectiveness of some capabilities across different industries);
and “dependent on market animation and learning methods” can
be common among technology-based companies [43, 41, 44].
In the context of the high velocity genomics-based
biopharmaceutical markets, dynamic capabilities are dependent
on the generation of new knowledge for increasingly specific
patient populations. Moreover, firms with dynamic capabilities
employ unique types of adaptive knowledge which can create
activities as real-time information, prototyping, multi-criteria
decision-making, and experimenting in an iterative and
cognitive way, which leads to unpredictable outcomes [41].
Biopharmaceutical companies must adapt to fast-changing
markets and rapid learning processes [45]. This environment
necessitates the significance of learning from experience in
order to create dynamic capabilities [46]. Studies demonstrate
that the learning mechanism, rather than detailed a priori plans,
plays an important part of the evolution of dynamic capabilities
for firms. Repeated practices (in activities such as acquisitions,
integration, and getting rid of resources) which lead to crucial
gain of specific and tacit knowledge for firms [47, 48, 49]. What
is more important about learned knowledge is the firm’s ability

to systemize, articulate, share, and embed the acquired
knowledge into procedures and know-how as a way to a faster
organizational learning [48, 41, 65, 58]. Managers must acquire
information from mistakes, failures and crises (real time and/or
simulated scenarios) [50, 40, 51].
Experience and speed can also improve the creation of
dynamic capabilities through rapid acquisition of experience
that can strengthen managers’ decision-making ability, improve
knowledge, and hone insights [48, 41]. Accumulation of
experience in the selection and jettison of the products and
businesses based on distinctive market changes is another
important parts of dynamic capabilities vital for firms [46, 52].
Lastly, sequence appears to be important in generating dynamic
capabilities [49, 41]. By assuming that dynamic capabilities as
being modular and composed of smaller components
(ingredients), the order of composition and implementation of
smaller modules into a dynamic capability (recipe) is crucial for
firms.
More recently, Pisano describes firm’s capability problem
as a problem being about selecting between different
identification strategies for needed kind of capabilities. Each
firm has to choose to either go deep or broad, general or market
specific in terms of dynamic capabilities [53].
In sum, competitive advantage in high tech environments
such as biopharmaceuticals is often episodic, fleeting and
erratic. Hence, continual acquisition and rethinking of
intangible assets and resources (sensing, seizing, and
transforming) in order to generate and manage dynamic
capabilities is vital to firms’ success.

Rare Disease Focused
Biopharmaceutical
Company

Figure 3. Geographical Locations of Rare Disease-based Companies

Where market capitalization is the total value of a
company’s balance sheet and total cash is the sum of all the cash
that a firm has in its books [54]. Descriptive statistics for the
collected 24 companies are shown in Table 1.
TABLE 1: DESCRIPTIVE STATISTICS FOR THE STUDIED COMPANIES

IV. DATA COLLECTION AND METHODOLOGY
As the next step, by considering the disruptive biopharma
sub-sector of rare disease being directed by breakthroughs in
genomics, we used the Biocentury database which tracks over
1,300 public and 4,000 private biotech companies worldwide
from 1995-present with goal of finding elements of dynamic
capabilities in building, creating and capturing value in the
studied companies. We identified 24 publicly-traded rare
disease-focused biotech companies, 18 of which focus
exclusively on gene therapy, during the 1995-2017 period [25].
In the United States, a rare disease is defined as one that affects
fewer than 200,000 people. According to the Genetic and Rare
Diseases Information Center (GARD) at the National Institutes
of Health, there are over 7,000 rare diseases with less than five
percent having an approved treatment. The studied companies
are primarily concentrated in biotech clusters located in
Massachusetts and California (Figure 3).
Data were collected for each company in 11 categories
(revenue, enterprise value, net income, retained earnings/ total
financing, cash, number of employees, CEO tenure, number of
board of director members, year of foundation, year of IPO,
clinical/commercial products, and number of total products) on
May 5th, 2017. The definition for each of these criteria is shown
in Table 2. The enterprise value (EV) has been defined as
follows:

The drug development process is lengthy and risky, with
development times of 7.5 to 19 years [55]. To determine the
status of each company in terms of NPD, data from their drug
pipelines were collected for discovery, preclinical, Phase 1-3,
and commercialization. The feasibility, iterative testing, and
safety-related information are collected during preclinical
development. In the first phase of clinical trials new drug
products or treatments are examined on a small number of
subjects to assess safety and dosage. The second phase involves
further evaluation of a drug’s safety and efficacy by being tested

on a larger population. In the third phase, the drug’s
effectiveness, side effects, and safety is examined on a larger,
statistically significant group of patients versus an active
control (e.g., placebo or current standard of care).
Each of these variables that are included in our statistical
analysis fall under one of the three asset criteria. These criteria
are finance-related, organizational related, and product related.
The sub-criteria of each of these asset types can is shown in
Table 3.
In order to assess the relationships between the enterprises
value of the studied firms with these financial, organizational,
and product attributes in the disruptive biopharma sub-sector of
rare diseases, this study uses a multi-variate regression analysis.
TABLE 2. VARIABLE DEFINITIONS

TABLE 3. ASSET TYPES IN THIS STUDY
Type of Asset

Sub-Criteria

Finance Assets

Revenue, net income, cash and retained
earnings

Organizational Assets

Number of employees, CEO tenure, and
number of the board of directors’
members, year of foundation, and year of
IPO

Product Assets

Number of products in various stages of
development

The dependent variable ‘Enterprise Value’ is analyzed with
regards to independent variables with respect to correlation (r),
p-value (p), and R-squared (R2). Correlation is the degree which
two metric variables are related in a linear manner. In this case,
(0 to (-) 0.3 is considered as weak correlation; (-) 0.3 to (-) 0.5
is considered medium correlation; and (-) 0.5 to (-) 1.0 is
considered as strong correlation. Negative correlations mean
that an increase or decrease in the independent variable would
result in the decrease or increase in the dependent value. The pvalue shows the significance (p <0.05) of the hypothesis. This
means that if the p-value for each of the tests is >0.05 we reject
the hypothesis (with 95% confidence). However, if the p-value
is <0.05, we accept the hypothesis and consider the underlying
assertion valid. Also, R2 refers to the percentage of ‘Enterprise
Value (EV)’ that can be explained by different independent
variables. In other words, R2 determines the proportion of the
variance in EV that can be predicted using the tested
independent variable. Finally, the non-standardized coefficient
shows the amount of unit changes in the “Enterprise Value”
with respect to changes in each independent variable. The
results of regression tests and scatter plots are discussed next.
As initial step, the linear relationship between the
independent variable (EV) and the dependent variables should
be checked. For this purpose, scatter plots are used to determine
if there is a good linear relationship between EV and different
independent variables. Based on the linear R-square values,
only the variables with medium or high ability to explain the
variability of the response data around their mean were selected
(Figure 4). As a result, revenue, retained earnings, number of
employees, and total number of products were chosen for
consideration. Cash was omitted from the analysis despite its
higher R-square value due to the fact that it is a part of EV
formula in order to avoid redundancy. Multivariate regression
analysis (95% confidence) was applied to the selected four
criteria in order to study their potential effects on the EV of 24
rare-disease focused, genomics based companies in US.

significant p-values regarding EV, number of products was the
third correlated variable at 55% (Table 6).
Table 8 shows the F-test with the null hypothesis that the
model explains zero variance in the EV (H0: R2=0). As the result
of the F-test is highly significant, we reject the null hypothesis
and can conclude that the model explains a significant amount
of the variance in the studied companies’ EV.
TABLE 4. DESCRIPTIVE STATISTICS FOR ANALYZED VARIABLES
Descriptive Statistics
EV

Mean

Std. Deviation

N

$2,751.68

$6,199.315

24

Revenue

$262.02

$669.037

24

Retained Earnings

-$277.46

$538.745

24

Employees

400.5000

712.92520

24

Total Products

8.7083

5.47309

24

TABLE 5. REGRESSION RESULTS
Coefficients
Std Coeff

Model

t

Sig.

95.0% Conf. Interval
for B
LB

UB

0.84

0.40

-670.70

1576.65

Beta
(Constant)
Revenue

0.21

2.34

0.03

0.21

3.84

Retained
Earnings

0.07

1.18

0.25

-0.68

2.46

Employees

0.78

7.95

0.00

5.02

8.61

Total
Products

-0.07

-1.21

0.04

-224.36

59.38

a. Dependent Variable: EV
TABLE 6. CORRELATIONS
Correlations

Figure 4: Scatter Plots for Independent Variables against EV

EV

Rev

Ret.
Earn

Employee

Tot. Prod

EV

1.00

0.91

0.73

0.96

0.55

Rev

0.91

1.00

0.80

0.83

0.37

Ret. Earn

0.73

0.80

1.00

0.62

0.15

Employee

0.96

0.83

0.62

1.00

0.68

Tot. Prod

0.55

0.37

0.15

0.68

1.00

The descriptive statistics for the variables that were analyzed
with regards to their R-squared values in the previous step can
be seen in Table 4. The results in Table 5 indicate that
‘Revenue’, ‘Number of Employees’, and ‘Total Number of
Products’ have predictive power of ‘Enterprise Value’ for the
studied rare disease companies. The four selected independent
values account for explaining about 96% (adjusted R-square)
percent of EV value variances for the studied companies (Table
7). In this section, the adjusted R-square has been used in order
to reflect the number of predictors in the model. The decrease
in the adjusted R-square compared to the R-square shows that
the predictor improves the model by less than expected by
chance. The standardized coefficients in Table 5 also highlight
the impact of number of employees on EV as the highest
predictor.
Furthermore, number of employees and revenue were found
to have significant correlations with the Enterprise Value at
96% and 91% respectively. Among the three variables that had

Pearson Correlation

V. RESULTS & DISCUSSION

TABLE 7. MODEL SUMMARY

Model

R

R
Square

Adjusted
R Square

Std. Error
of the
Estimate

1

.987a

0.974

0.968

$1,103.45

a. Predictors: (Constant), Total Products, Retained Earnings, Revenue,
Employees
b. Dependent Variable: EV

TABLE 8. ANOVA
ANOVA
Sum of Sq

df

Mean Sq

F

Sig.

Regressio
n

860790145.29

4

215197536

176.73

.000b

Residual

23134548.15

19

1217607

Total

883924693.45

23

To conclude, the enterprise values in the rare disease
focused, genomics based companies that were studied is
correlated with number of employees, their revenues, and the
number of products in the portfolios. These results can re-stress
the importance of tangible and intangible assets and capabilities
such as employee knowledge (tacit and explicit) and new
product development which both have been identified as
dynamic capabilities in the literature [56, 57, 9, 44, 41, 58].
VI. CONCLUSION

a. Dependent Variable: EV
b. Predictors: (Constant), Total Products, Retained Earnings, Revenue,
Employees

Finally, the normality of the residuals were checked with
a normal P-P plot in order to make sure that the points
generally follow the normal line without any strong
deviations. Figure 5 indicates that the residuals are normally
distributed. The results were also checked for multicollinearity in the multi-variate regression model and all
included independent variables were in the acceptable ranges
(as shown in table 9) in terms of tolerance (above 0.1) and
variance inflation factor (below 10). This shows that there is
correlation between predictors (revenue, number of
employees, retained earnings, and number of products).

Figure 5. Normal P-P Plot of Regression Standardized Residual
TABLE 9.COLLINEARITY STATISTICS

Collinearity Statistics
Tolerance

VIF

Revenue

0.157

6.351

Retained Earnings

0.322

3.103

Employees

0.142

7.066

Total Products

0.385

2.600

Biopharma companies have to constantly deal with intense
financial, competitive, regulative, technological, and market
fluctuation pressures. Amid the high change rates, competitive
advantage can be evasive and short-lived. Therefore, it is
imperative for companies to constantly morph and manage their
tangible and intangible assets and resources (i.e., sensing,
seizing, transforming) in order to be successful and/or survive.
Multiple examples of dynamic capabilities in technology-based
firms stress the need to respond to market price changes,
acquisition/forming alliances with goals of asset and
organizational reconfiguration, product innovation for
organizational renewal, and resource divestment [59, 60, 61, 62,
63].
In order to earn these capabilities and add value, it is crucial
for high-tech companies to attract expertise (i.e., employees in
different levels of the organization such as researchers and
board of director members) in order to guide company towards
competitive advantage and commercial success. Furthermore,
the aggregation of skilled and innovative employees lead to new
product innovation and lead companies into a more flexible and
efficient product pipeline. The knowledge and experience that
the workforce can bring can be seen as a cumulative bolstering
factor in leveraging dynamic capabilities which can be
recognized, understood, and transformed in order to align with
company goals and commercial success (i.e., increasing returns
in enterprise value). In other words, technology managers’ duty
does not end on managing the finance-related criteria of the
technology. Their duty also encapsulate management of human
resources, asset configuration, and strategic alliances efficiently
towards higher velocity and more efficient innovation. Strong
dynamic capabilities can be formed with the accumulation of
experience, articulation and codification of knowledge, and an
adaptive ability to change the way they solve problems as the
environment transforms [64]. In the case of biopharmaceutical
companies, more efficient, prolific, and flexible employees can
guide company to more successful NPD and a more efficient
R&D pipeline.
The disruptive genomics transformation equips rare diseasebased biopharmaceutical companies with the opportunity to
generate great value and shift the entire global industry from
mass market to personalized medicine. Taking advantage of
genomics and new technologies can direct biopharma firms to
improve product innovation and boost their chances of
attracting employee expertise, insightful boards of directors,
and management teams. Biopharma managers should be alert in
sensing the opportunities, threats, and resources followed by

seizing and reconfiguring the acquired knowledge to fit their
organization in order to gain and sustain competitive
advantages.
In this study, twenty-four rare disease-focused biopharma
companies were studied and several variables were tested with
respect to enterprise value. The companies were analyzed as a
group of rare disease firms. We found that variables such as
number of employees, revenue, and number of products are
correlated (in that order) with the enterprise value in rare
disease-focused biopharma companies.
As an extension of this study, we would suggest comparing
these results against the entire biotechnology industry as whole
to better differentiate specialized rare disease companies.
Furthermore, these variables can be analyzed based on the size
of the companies (small, medium, and large cap). Individual
linear regression can be implemented in order to take a deeper
look into the relations of different variables compared to EV.
Moreover, as number of employees was shown to be crucial to
the EV values of the studied companies, further study into what
kind of employees would have the most significant impact on
biopharma companies might be insightful. Also, more research
into the effects of the biopharma geographical clusters is
intriguing as there is a definite geographical impact in terms of
knowledge transfer and cross-pollination between firms in high
velocity technological industries (as these areas employ more
skilled employees and therefore accumulate more knowledge
and enterprise value (shown as darker colored states) as shown
in Figure 6).

Figure 6. Active Geographical Clusters for Rare-disease Biopharma
Companies and Respective Number of Employees

Using a dynamic capabilities lens, this paper studied the
influence of genomics generally and gene therapy specifically
on the rare disease sector of the biopharmaceutical industry.
This study found that increasing rates of cumulative returns
depends on accumulating knowledge-based employees and
expanding product portfolios of disruptive genomics-based

technologies for treating rare diseases. Also, this study stresses
the significance of constructing the capability and capacity to
attract expertise and accrue know-how for new product
innovations and viable competitive advantage. The findings of
this paper highlight the influence of decreased cost and
increased attraction in prospective prevalence of genomics and
its position as a disruptive innovation with impact on the
biotech industry.
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